Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

HIV-1

This page shows the latest HIV-1 news and features for those working in and with pharma, biotech and healthcare.

Gilead’s Biktarvy received EC approval for the treatment of HIV in paediatric populations

Gilead’s Biktarvy received EC approval for the treatment of HIV in paediatric populations

HIV. In study 1474, treatment outcomes with Biktarvy were evaluated in adolescents between the ages of 12 to less than 18 years weighing at least 35kg (treatment cohort 1), in children ... The company reported that no new adverse reactions were observed

Latest news

More from news
Approximately 3 fully matching, plus 69 partially matching documents found.

Latest Intelligence

  • Awards or not, what really matters is... can you make it mean something? Awards or not, what really matters is... can you make it mean something?

    Earlier that year the U=U message had been scientifically proven and endorsed by all of the UK’s leading HIV charities, as well as over 1, 000 organisations from 102 ... This was big news, a landmark moment for the HIV community: undetectable =

  • Keeping up the fight against HIV and using the lessons to tackle other threats Keeping up the fight against HIV and using the lessons to tackle other threats

    Improving access. Gilead is now progressing on a first-in-class inhibitor of the HIV-1 capsid function that could be administered just twice yearly and is advancing with research to ... He added: “We have medicines that provide good treatments for a

  • No incentive for a cure No incentive for a cure

    The paradox of ‘cost-effective but unaffordable’ life-saving medicines. Type 1 diabetes, heart failure, HIV - all examples of diseases that have transitioned from fatal conditions to chronic diseases, thanks to

  • Pharma deals during July 2012 Pharma deals during July 2012

    $700m). It has completed a phase I volunteer study. There have not been many deals in the HIV area over the past few years. ... 178. Chimerix / Merck &Co. Licence. Lipid antiviral conjugate in phase 1 for treatment of HIV.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

  • 'Fake news': battling misinformation in healthcare

    However, if you were to read the  accelerated preview in  Nature you would see that the very first line of the abstract is “A cure for HIV-1 remains unattainable as ... For example, even subtly suggesting there will soon be a cure for HIV inflates

  • World AIDS Day 2018: Fighting the stigma surrounding HIV

    1. Despite there being no cure for HIV, considerable progress has been made in treating the infection over the last 30 years. ... 1, 2. Even with this progress, the stigma, ignorance and misconceptions surrounding HIV and those living with it remain a

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
EPG Health

REACH, ENGAGE & MEASURE HCPs ONLINE - Accomplish meaningful engagement via Medthority (www.medthority.com), a trusted independent medical education website. Support...

Latest intelligence

The speed of science and the pace of comms
Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
Improving cardiovascular disease care and awareness
Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
Virtual Patient Engagement Program: A Customer Story
Our client wanted to better understand the needs, preferences, and treatment gaps among adult patients with a rare genetic disease......

Quick links